ArticleWorld journal of cardiology2026
Oral anticoagulant therapy and outcomes in new-onset atrial fibrillation during acute myocardial infarction: A systematic review and meta-analysis.
Article in World journal of cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNew-onset atrial fibrillation (NOAF) is observed in 2%-21% of patients with acute myocardial infarction (AMI) and is associated with adverse outcomes, including increased mortality, heart failure, and stroke. Despite guideline recommendations the long-term role of oral anticoagulant (OAC) therapy in this population remains unclear. Most randomized clinical trials evaluating anticoagulation excluded patients with NOAF following AMI, creating a gap in high-quality evidence. Whether long-term OAC therapy improves prognosis without excess bleeding risk in this setting remains uncertain. We hypothesized that OAC use reduces mortality in patients with NOAF complicating AMI.
aimTo determine the efficacy and safety of long-term OAC therapy in patients with NOAF during AMI.
methodsWe conducted a systematic review of the PubMed and eLIBRARY databases through March 2025 following predefined patient, intervention, comparison, outcome criteria. Eligible observational studies included patients with AMI and newly detected atrial fibrillation during the index event who were prescribed OAC therapy with available outcome data. Methodological quality was evaluated using the Quality in Prognosis Studies tool. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using a random-effects model. Primary outcomes were all-cause mortality, ischemic stroke, and major bleeding.
resultsFour studies including 7158 patients with a follow-up range of 1.0-8.6 years were analyzed. Long-term OAC therapy significantly reduced all-cause mortality (25.3%
conclusionLong-term OAC therapy after AMI with NOAF reduced mortality without consistent bleeding increase though findings mainly reflect warfarin-era practice and not direct OACs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.